Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seema Singhal

Showing results (121-130 of 140) with videos related to

Pageof 14
Sort By:
The New England Journal of Medicine|June 27, 2003
A phase 2 study of bortezomib in relapsed, refractory myelomaPaul G Richardson, Bart Barlogie, James Berenson, et al.
Blood|August 16, 2005
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myelomaSagar Lonial, Edmund K Waller, Paul G Richardson, et al.
British Journal of Haematology|August 31, 2006
Long-term outcome results of the first tandem autotransplant trial for multiple myelomaBart Barlogie, Guido J Tricot, Frits van Rhee, et al.
Blood|February 5, 2011
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3Meletios Dimopoulos, Robert Kyle, Jean-Paul Fermand, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 27, 2009
NCCN task force: clinical utility of PET in a variety of tumor typesDonald A Podoloff, Douglas W Ball, Edgar Ben-Josef, et al.
British Journal of Haematology|May 29, 2010
Monoclonal gammopathy of undetermined significance: a consensus statementJames R Berenson, Kenneth C Anderson, Robert A Audell, et al.
Blood Cancer Journal|February 6, 2019
Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myelomaA Keith Stewart, Amrita Y Krishnan, Seema Singhal, et al.
International Journal of Cancer|June 8, 2026
Clinical Validation of Four Point-of-Care High-Risk HPV Assays, Including Two Reduced-Valency Assays, for Cervical Cancer Screening in Low-Resource SettingsNeerja Bhatla, MaryLuz Rol, Seema Singhal, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 12, 2013
Multiple myeloma, version 1.2013Kenneth C Anderson, Melissa Alsina, William Bensinger, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 12, 2012
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013Kenneth C Anderson, Melissa Alsina, William Bensinger, et al.
Pageof 14

Showing results (121-130 of 140) with videos related to

Sort By:
Pageof 14
The New England Journal of Medicine|June 27, 2003
A phase 2 study of bortezomib in relapsed, refractory myelomaPaul G Richardson, Bart Barlogie, James Berenson, et al.
Blood|August 16, 2005
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myelomaSagar Lonial, Edmund K Waller, Paul G Richardson, et al.
British Journal of Haematology|August 31, 2006
Long-term outcome results of the first tandem autotransplant trial for multiple myelomaBart Barlogie, Guido J Tricot, Frits van Rhee, et al.
Blood|February 5, 2011
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3Meletios Dimopoulos, Robert Kyle, Jean-Paul Fermand, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 27, 2009
NCCN task force: clinical utility of PET in a variety of tumor typesDonald A Podoloff, Douglas W Ball, Edgar Ben-Josef, et al.
British Journal of Haematology|May 29, 2010
Monoclonal gammopathy of undetermined significance: a consensus statementJames R Berenson, Kenneth C Anderson, Robert A Audell, et al.
Blood Cancer Journal|February 6, 2019
Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myelomaA Keith Stewart, Amrita Y Krishnan, Seema Singhal, et al.
International Journal of Cancer|June 8, 2026
Clinical Validation of Four Point-of-Care High-Risk HPV Assays, Including Two Reduced-Valency Assays, for Cervical Cancer Screening in Low-Resource SettingsNeerja Bhatla, MaryLuz Rol, Seema Singhal, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 12, 2013
Multiple myeloma, version 1.2013Kenneth C Anderson, Melissa Alsina, William Bensinger, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 12, 2012
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013Kenneth C Anderson, Melissa Alsina, William Bensinger, et al.
Pageof 14